Loïc Ysebaert

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun et al. · Blood Advances · 2020 · 404 citations · Full text

Medicine, Oncology, Cell Therapy +16

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

Arnaud Jaccard, Nathalie Gachard, Benôıt Marin et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier et al. · New England Journal of Medicine · 2018 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Richard Delarue, Hervé Tilly, Nicolas Mounier et al. · The Lancet Oncology · 2013 · 303 citations

Medicine, Oncology, Pharmacotherapy +4

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F. Seymour, Pierre Feugier et al. · Journal of Clinical Oncology · 2019 · 278 citations · Full text

Medicine, Immunology, Oncology +10